A Study of Baricitinib and Birth Control Pills in Healthy Females
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out how the body absorbs and breaks down a common
birth control pill called Microgynon when it is given with the study drug called baricitinib.
Safety and the body's ability to tolerate baricitinib and Microgynon will also be studied.
The study will last approximately 6 weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ethinyl Estradiol-Norgestrel Combination Ethinyl estradiol, levonorgestrel drug combination